company background image
VPH

Valeo Pharma TSX:VPH Stock Report

Last Price

CA$0.56

Market Cap

CA$45.8m

7D

-6.7%

1Y

-36.4%

Updated

04 Jul, 2022

Data

Company Financials +
VPH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

VPH Stock Overview

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada.

Valeo Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Valeo Pharma
Historical stock prices
Current Share PriceCA$0.56
52 Week HighCA$0.97
52 Week LowCA$0.45
Beta3
1 Month Change13.13%
3 Month Change-9.68%
1 Year Change-36.36%
3 Year Change0%
5 Year Changen/a
Change since IPO-13.85%

Recent News & Updates

Jun 24
Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

The analysts covering Valeo Pharma Inc. ( TSE:VPH ) delivered a dose of negativity to shareholders today, by making a...

Jun 17
Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

It's been a pretty great week for Valeo Pharma Inc. ( TSE:VPH ) shareholders, with its shares surging 12% to CA$0.56 in...

Shareholder Returns

VPHCA HealthcareCA Market
7D-6.7%-1.3%-0.8%
1Y-36.4%-34.9%-5.0%

Return vs Industry: VPH underperformed the Canadian Healthcare industry which returned -34.9% over the past year.

Return vs Market: VPH underperformed the Canadian Market which returned -5% over the past year.

Price Volatility

Is VPH's price volatile compared to industry and market?
VPH volatility
VPH Average Weekly Movement6.0%
Healthcare Industry Average Movement7.5%
Market Average Movement10.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market4.4%

Stable Share Price: VPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: VPH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003100Steve Saviukhttps://www.valeopharma.com

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson’s Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic.

Valeo Pharma Fundamentals Summary

How do Valeo Pharma's earnings and revenue compare to its market cap?
VPH fundamental statistics
Market CapCA$45.75m
Earnings (TTM)-CA$21.60m
Revenue (TTM)CA$18.06m

2.5x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VPH income statement (TTM)
RevenueCA$18.06m
Cost of RevenueCA$12.13m
Gross ProfitCA$5.93m
Other ExpensesCA$27.53m
Earnings-CA$21.60m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin32.83%
Net Profit Margin-119.62%
Debt/Equity Ratio-655.2%

How did VPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VPH?

Other financial metrics that can be useful for relative valuation.

VPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.5x
Enterprise Value/EBITDA-4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VPH's PS Ratio compare to its peers?

VPH PS Ratio vs Peers
The above table shows the PS ratio for VPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.1x
TCAN TransCanna Holdings
2xn/aCA$7.8m
BLMH Bloom Health Partners
0.3xn/aCA$7.7m
HLS HLS Therapeutics
5x35.2%CA$390.0m
XCX Greenrise Global Brands
13.1xn/aCA$8.5m
VPH Valeo Pharma
2.5x36.0%CA$45.8m

Price-To-Sales vs Peers: VPH is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (5.1x).


Price to Earnings Ratio vs Industry

How does VPH's PE Ratio compare vs other companies in the CA Healthcare Industry?

Price-To-Sales vs Industry: VPH is expensive based on its Price-To-Sales Ratio (2.5x) compared to the Canadian Healthcare industry average (1.3x)


Price to Sales Ratio vs Fair Ratio

What is VPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: VPH is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).


Share Price vs Fair Value

What is the Fair Price of VPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VPH (CA$0.56) is trading below our estimate of fair value (CA$17.04)

Significantly Below Fair Value: VPH is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VPH's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Valeo Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


66.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: VPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VPH is expected to become profitable in the next 3 years.

Revenue vs Market: VPH's revenue (36% per year) is forecast to grow faster than the Canadian market (6.5% per year).

High Growth Revenue: VPH's revenue (36% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Valeo Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-52.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VPH is currently unprofitable.

Growing Profit Margin: VPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VPH is unprofitable, and losses have increased over the past 5 years at a rate of 52.5% per year.

Accelerating Growth: Unable to compare VPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-68.2%).


Return on Equity

High ROE: VPH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Valeo Pharma's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VPH has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VPH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VPH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Valeo Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Steve Saviuk (63 yo)

19.5yrs

Tenure

CA$259,344

Compensation

Mr. Steven Saviuk, also known as Steve, CA, serves as Independent Director at Cluny Capital Corp. since April 15, 2021. He serves as Vice Chairman of Valeo Pharma Inc. since January 18, 2021 and is its Dir...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD201.26K) is about average for companies of similar size in the Canadian market ($USD191.19K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: VPH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: VPH's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Valeo Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Valeo Pharma Inc.
  • Ticker: VPH
  • Exchange: TSX
  • Founded: 2003
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: CA$45.755m
  • Shares outstanding: 81.71m
  • Website: https://www.valeopharma.com

Number of Employees


Location

  • Valeo Pharma Inc.
  • 16667 Hymus Boulevard
  • Kirkland
  • Quebec
  • H9H 4R9
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/04 00:00
End of Day Share Price2022/07/04 00:00
Earnings2022/04/30
Annual Earnings2021/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.